CRBN and cancer: In a prostate cancer model, castration-resistant prostate cancer (CRPC) cells transformed into NE-like cancer upon repeated enzalutamide treatment exhibited increased DNA accessibility at the CRBN promoter region—comparable to that observed in the H660 NEPC cell line.